Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 54 entries
View as:

Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03841201 Org: User:
Start: 06/12/19 End: 05/02/23 Due: 05/02/24

Study With Paclitaxel +/- Ramucirumab in Patients With Squamous-cell Carcinoma of the Esophagus After Prior Therapy

Phase: N/A Priority: Normal
NCT ID: NCT03762564 Org: User:
Start: 03/08/19 End: 11/25/22 Due: 11/25/23

Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery

Phase: N/A Priority: Normal
NCT ID: NCT04177953 Org: User:
Start: 02/04/19 End: 01/30/25 Due: 01/30/26

Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05101629 Org: User:
Start: 05/11/22 End: 12/31/25 Due: 12/31/26

Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01956149 Org: User:
Start: 09/30/13 End: 04/04/18 Due: 04/04/19

FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)

Phase: N/A Priority: Normal
NCT ID: NCT02661971 Org: User:
Start: 06/30/16 End: 06/20/22 Due: 06/20/23

Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function

Phase: N/A Priority: Normal
NCT ID: NCT04522908 Org: User:
Start: 10/12/20 End: 10/04/24 Due: 10/04/25

Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06440993 Org: User:
Start: 08/23/24 End: 04/30/28 Due: 04/30/29

Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma

Phase: N/A Priority: Normal
NCT ID: NCT05080790 Org: User:
Start: 11/15/21 End: 01/20/25 Due: 01/20/26

New Prospective Expanded German Registry of Incidental Gallbladder Carcinoma (PERSUASION)- a Permanent Platform Including All Kind of Biliary Tract Cancers (BTC)

Phase: N/A Priority: Normal
NCT ID: NCT04896931 Org: User:
Start: 07/12/22 End: 09/30/29 Due: 09/30/30

Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06123468 Org: User:
Start: 04/17/24 End: 03/31/27 Due: 03/31/28

CaboCHECK - Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following Prior Systemic Check Point Inhibition Therapy: a Retrospective, Non-interventional Study

Phase: N/A Priority: Normal
NCT ID: NCT04147143 Org: User:
Start: 03/08/19 End: 02/28/21 Due: 02/28/22

Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease

Phase: N/A Priority: Normal
NCT ID: NCT04462276 Org: User:
Start: 07/28/20 End: 09/02/24 Due: 09/02/25

Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05268510 Org: User:
Start: 09/15/22 End: 01/09/25 Due: 01/09/26

PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04119362 Org: User:
Start: 10/24/19 End: 06/30/23 Due: 06/30/24

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

Phase: N/A Priority: Normal
NCT ID: NCT04318938 Org: User:
Start: 03/30/20 End: 01/16/26 Due: 01/16/27

Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery

Phase: N/A Priority: Normal
NCT ID: NCT05713838 Org: User:
Start: 08/28/23 End: 12/31/28 Due: 12/31/29

OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients

Phase: N/A Priority: Normal
NCT ID: NCT03698227 Org: User:
Start: 11/12/18 End: 06/25/20 Due: 06/25/21

PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)

Phase: N/A Priority: Normal
NCT ID: NCT04484636 Org: User:
Start: 10/28/20 End: 12/31/24 Due: 12/31/25

Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients with Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT03081143 Org: User:
Start: 05/10/17 End: 12/31/25 Due: 12/31/26

Intravenous Ferric Carboxymaltose vs. Oral Iron Substitution in Patients With Metastatic Colorectal Cancer (CRC) and Iron Deficiency Anemia: a Randomized Multicenter Treatment Optimization Study.

Phase: N/A Priority: Normal
NCT ID: NCT02469480 Org: User:
Start: 03/31/15 End: 08/31/20 Due: 08/31/21

Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06178445 Org: User:
Start: 04/17/24 End: 04/30/28 Due: 04/30/29

Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction

Phase: N/A Priority: Normal
NCT ID: NCT04517747 Org: User:
Start: 10/15/20 End: 01/20/23 Due: 01/20/24

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

Phase: N/A Priority: Normal
NCT ID: NCT06856837 Org: User:
Start: 04/01/25 End: 12/31/29 Due: 12/31/30

Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT06680622 Org: User:
Start: 03/03/25 End: 03/31/28 Due: 03/31/29